Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Incyte Corp INCY

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

NDAQ:INCY - Post Discussion

Incyte Corp > Market Perform Recommendation Issued On INCY By BMO Capital
View:
Post by whytestocks on Apr 30, 2024 10:15pm

Market Perform Recommendation Issued On INCY By BMO Capital

Just In: $INCY Market Perform Recommendation Issued On INCY By BMO Capital2024-04-30 21:15:01 ET BMO Capital analyst issues MARKET PERFORM recommendation for INCY on April 30, 2024 04:29PM ET. The previous analyst recommendation was Market Perform. INCY was trading at $52.05 at issue of the analyst recommendation. The overall analyst consensus...INCY - Market Perform Recommendation Issued On INCY By BMO Capital
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities